Intense bioprocessing competition
New product introductions and alternative technologies can reduce demand for existing products.
- Scope
- Filtration, chromatography, process analytics and proteins
- Materiality
- high
Repligen Corporation
Repligen Corp. is a U.S.-based life sciences company focused on bioprocessing technologies and systems used in the manufacture of biological drugs. Its portfolio spans filtration, chromatography, process analytics and proteins products sold to biopharmaceutical companies, CDMOs and other life science customers worldwide.
18,1 %
52,3 %
6,6 %
+16,4 %
8.37
7.12
| % | |
|---|---|
| Filtration products | 55% Single-use and reusable filtration technologies used in upstream and downstream bioprocessing. |
| Chromatography products | 21% Purification products including columns and related chromatography systems for biologics manufacturing. |
| Process analytics products | 11% Instrumentation and desktop PAT tools used to monitor and optimize bioprocess operations. |
| Proteins products | 13% Affinity ligands and protein-based products used in purification and separation workflows. |
Repligen sells primarily to global biopharmaceutical companies, CDMOs and other life science companies that manufacture...
- Global biopharmaceutical companiesprimary
Buy filtration, chromatography and analytics tools for biologics production and process optimization.
- CDMOsprimary
Buy integrated bioprocessing products to support outsourced manufacturing for multiple clients.
- Life science integratorssecondary
Buy across franchises to build connected unit operations and complete bioprocess workflows.
- Diagnostics companiessecondary
Buy selected products and technologies where bioprocessing or related applications overlap.
- Laboratory researchersemerging
Buy certain products for research and development workflows rather than commercial manufacturing.
Repligen operates globally from its headquarters in Waltham, Massachusetts, with offices and manufacturing sites in the...
- •Headquartered in Waltham, Massachusetts, United States
- •Manufacturing and offices span the United States, Europe and Asia
- •2025 revenue mix: North America 49%, Europe 34%, APAC/ROW 17%
- •Global footprint supports local sales, service and technical support
- •Foreign currency exposure matters because revenue and costs are global
Repligen’s strategy is to broaden its bioprocessing platform across filtration, chromatography, process analytics and...
01
Build integrated bioprocessing solutionsmedium-term
Customers increasingly want connected unit operations rather than standalone tools.
02
Expand process analytics and PATshort-term
Actionable process data helps customers improve development and manufacturing efficiency.
03
Broaden technology through acquisitionsmedium-term
Acquired technologies can extend the portfolio and accelerate market access.
04
Invest in commercial and manufacturing capacityshort-term
Global support and reliable supply are critical in regulated biologics production.
Repligen faces intense competition in a fast-changing bioprocessing market, where new technologies can displace...
Acquisition and goodwill impairment
Acquired technology and customer relationships may not generate expected returns.
- Scope
- Purchased intangibles and goodwill
- Materiality
- high
Foreign exchange volatility
A large share of revenue and expenses is denominated outside the U.S. dollar.
- Scope
- Europe and APAC operations
- Materiality
- high
Supply chain inflation and tariffs
Raw materials, logistics and trade actions can raise costs or disrupt deliveries.
- Scope
- Global manufacturing and sourcing
- Materiality
- high
Cybersecurity and data incidents
Sensitive employee, IP and vendor data are stored across internal and third-party systems.
- Scope
- IT systems and vendor networks
- Materiality
- medium
Revenue recognition for products and royalties
Can create quarter-to-quarter variability in reported revenue
Goodwill and intangible asset impairment
Impairment charges could materially reduce earnings and equity
Foreign currency translation
Affects comparability of reported results across periods
Acquisition accounting
Can affect amortization expense and future impairment risk
: 29.4.2026